Article Commentary: First Human Myoblast Transfer Therapy Continues to Show Dystrophin after 6 Years

Alameddine H.S. ; Louboutin J.P. ; Dehaupas M. Functional recovery induced by satellite cell grafts in irreversibly injured muscles. Cell Transplant. 3: 3–14; 1994.

Anderson W.F. The ADA human gene therapy clinical protocol. Hum. Gene Ther. 1: 327–362; 1990.

Anderson W.F. Human gene therapy. Science 256: 808–813; 1992.

Barr E. ; Leiden J.M. Systemic delivery of recombinant proteins by genetically modified myoblasts. Science 254: 1507–1509; 1991.

Blau H.M. ; Springer M.L. Muscle-mediated gene therapy. N. Engl. J. Med. 333: 1554–1556; 1995.

Bonilla E. ; Samitt C.E. ; Miranda A.F. Duchenne muscular dystrophy: Deficiency of dystrophin at the muscle cell surface. Cell 54: 447–452; 1988.

Carlson B.M. The regeneration and transplantation of skeletal muscle. In: Seil F. , ed. Nerve, organ, and tissue regeneration: Research perspectives. New York: Academic Press; 1983: 431–454.

Chen M. ; Li H.J. ; Fang Q. Dystrophin cytochemistry in mdx mouse muscles injected with labeled normal myoblasts. Cell Transplant. 1: 17–22; 1992.

Chen S.S. ; Chien C.H. ; Yu H.S. Syndrome of deltoid and/or gluteal fibrotic contracture; An injection myopathy. Acta Neurol. Scand. 78: 167–176; 1988.

Chiu R.C-J. ; Zibaitis A. ; Kao R.L. Cellular cardiomyoplasty: Myocardial regeneration with satellite cell implantation. Ann. Thorac. Surg. 60: 12–18; 1995.

Culver K.W. ; Osborne W.R. ; Miller A.D. Correction of ADA deficiency in human T lymphocytes using retroviral-mediated gene transfer. Transplant. Proc. 23: 170–171; 1991.

Daar A.S. ; Fuggle S.V. ; Fabre J.W. The detailed distribution of HLA-A, B, C antigens in normal human organs. Transplantation 38: 287–298; 1984.

Dai Y. ; Roman M. ; Naviaux R.K. Gene therapy via primary myoblasts: Long-term expression of factor IX protein following transplantation in vivo. Proc. Natl. Acad. Sci. USA 89: 10892–10895; 1992.

Dhawan J. ; Pan L.C. ; Pavlath G.K. Systemic delivery of human growth hormone by injection of genetically engineered myoblasts. Science 254: 1509–1512; 1991.

Epstein S.L. Regulatory concerns in human gene therapy. Hum. Gene Ther. 2: 243–249; 1991.

Fang Q. ; Chen M. ; Li H.J. MHC-1 antigens on cultured human myoblasts. Transplant. Proc. 26: 3467; 1994.

Fex S. ; Jirmanova I. Innervation by nerve implants of “fast” and “slow” skeletal muscles of the rat. Acta Physiol. Scand. 76: 257–269; 1969.

Friedlander M. ; Fischman D.A. Immunological studies of the embryonic muscle cell surface. Antiserum to the profusion myoblast. J. Cell Biol. 81: 193–214; 1979.

Guerette B. ; Asselin I. ; Vilquin J.T. Lymphocyte infiltration following allo- and xenomyoblast transplantation in mdx mice. Muscle Nerve. 18: 39–51; 1995.

Gussoni E. ; Pavlath G.K. ; Lanctot A.M. Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation. Nature 356: 435–438; 1992.

Hamamori Y. ; Samal B. ; Tian J. Persistent erythropoiesis by myoblast transfer of erythropoietin cDNA. Hum. Gene Ther. 5: 1349–1356; 1994.

Hamamori Y. ; Samal B. ; Tian J. Myoblast transfer of human erythropoietin gene in a mouse model of renal failure. J. Clin Invest. 95: 1808–1813; 1995.

Hooper C. Duchenne therapy trials starting in U.S., Canada. J. NIH Res. 2: 30; 1990.

Huard J. ; Bouchard J.P. ; Roy R. Human myoblast transplantation: Preliminary results of 4 cases. Muscle Nerve 15: 550–560; 1992.

Jiao S. ; Schultz E. ; Wolff J.A. Intracerebral transplants of primary muscle cells: A potential platform for transgene expression in the brain. Brain Res. 575: 143–147; 1992.

Karpati G. ; Ajdukovic D. ; Arnold D. Myoblast transfer in Duchenne muscular dystrophy. Ann. Neurol. 34: 8–17; 1993.

Katagiri T. ; Yamaguchi A. ; Komaki M. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. J. Cell Biol. 127: 1755–1766; 1994.

Kessler D.A. ; Siegel J.P. ; Noguchi P.D. Regulation of somatic cell-therapy and gene therapy by the Food and Drug Administration. N. Engl. J. Med. 329: 1169–1173; 1993.

Kinoshita I. ; Vilquin J.-T. ; Guerette B. Very efficient myoblast allotransplantation in mice under FK-506 immunosuppression. Muscle Nerve 17: 1407–1415; 1994.

Koh G.Y. ; Soonpaa M.H. ; Klug M.G. Stable fetal cardiomyocyte grafts in the hearts of dystrophic mice and dogs. J. Clin. Invest. 96: 2034–2042; 1995.

Law P.K. Reduced regenerative capability of minced dystrophic mouse muscles. Exp. Neurol. 60: 231–243; 1978.

Law P.K. Beneficial effects of transplanting normal limb-bud mesenchyme into dystrophic mouse muscles. Muscle Nerve 5: 619–627; 1982.

Law P.K. Misrepresentation conspires against potential treatment for muscular dystrophy. IRB 17: 4–6; 1995.

Law P.K. ; Bertorini T.E. ; Goodwin T.G. Dystrophin production induced by myoblast transfer therapy in Duchenne muscular dystrophy. Lancet 336: 114–115; 1990.

Law P.K. ; Goodwin T.G. ; Fang Q. Long-term improvement in muscle function, structure and biochemistry following myoblast transfer in DMD. Acta Cardiomiol. 3: 281–301; 1991.

Law P. ; K; Goodwin T.G. ; Fang Q. Myoblast transfer therapy for Duchenne muscular dystrophy. Acta Paediatr. Jpn. 33: 206–215; 1991.

Law P.K. ; Goodwin T.G. ; Fang Q. Feasibility, safety, and efficacy of myoblast transfer therapy on Duchenne muscular dystrophy boys. Cell Transplant. 1: 235–244; 1992.

Law P.K. ; Goodwin T.G. ; Fang Q. Cell transplantation as an experimental treatment for Duchenne muscular dystrophy. Cell Transplant. 2: 485–505; 1993.

Law P. ; Goodwin T. ; Fang Q. Whole body myoblast transfer. Transplant. Proc. 26: 3381–3383; 1994.

Law P.K. ; Goodwin T.G. ; Li H.J. Histoincompatible myoblast injection improves muscle structure and function of dystrophic mice. Transplant. Proc. 20: 1114–1119; 1988.

Law P.K. ; Goodwin T.G. ; Wang M.G. Normal myoblast injections provide genetic treatment for murine dystrophy. Muscle Nerve 11: 525–533, 1988.

Law P.K. ; Yap J.L. New muscle transplant method produces normal twitch tension in dystrophic muscle. Muscle Nerve 2: 356–363; 1979.

Mendell J.R. ; Kissel J.T. ; Amato A.A. Myoblast transfer in the treatment of Duchenne's muscular dystrophy. N. Engl. J. Med. 333: 832–838; 1995.

Miller R.G. ; Pavlath G. ; Sharma K. Myoblast implantation in Duchenne muscular dystrophy: The San Francisco study. Neurology 42: 189–190; 1992.

Morandi L. ; Bernasconi P. ; Gebbia M. Lack of mRNA and dystrophin expression in DMD patients three months after myoblast transfer. Neuromusc. Disord. 5: 291–295; 1995.

Morishita R. ; Gibbons G.H. ; Horiuchi M. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc. Natl. Acad. Sci. USA 92: 5855–5859, 1995.

Partridge T.A. ; Morgan J.E. ; Coulton G.R. Conversion of mdx myofibers from dystrophin-negative to -positive by injection of normal myoblasts. Nature 337: 176–179; 1989.

Simonson G.D. ; Groskreutz D.J. ; Gorman C.M. Synthesis and processing of genetically modified human proinsulin by rat myoblast primary cultures. Hum. Gene Ther. 7: 71–78; 1996.

Soonpaa M.H. ; Koh G.Y. ; Klug M.G. Formation of nascent intercalated disks between grafted fetal cardiomyocytes and host myocardium. Science 264: 98–101; 1994.

Teboul L. ; Gaillard D. ; Staccini L. Thiazolidinediones and fatty acids convert myogenic cells into adiposelike cells. J. Biol. Chem. 270: 28183–28187; 1995.

Tremblay J.P. ; Malouin F. ; Roy R. Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy. Cell Transplant. 2: 99–112; 1993.

Vilquin J.T. ; Kinoshita I. ; Roy R. Cyclosphosphamide immunosuppression does not permit successful myoblast allotransplantation in mouse. Neuromusc. Disord. 5: 511–517; 1995.

Yao S.N. ; Smith K.J. ; Kurachi K. Primary myoblast-mediated gene transfer: persistent expression of human factor IX in mice. Gene Ther. 1: 99–107; 1994.